EGFR and non-small cell lung carcinoma: The median OS of 23.6 months and PFS of 5.6 months in this study were comparable to those reported previously, with the median OS exceeding 20 months following EGFR-TKIs, demonstrating promise in comparison to the median OS of 38.6 months and PFS of 18.9 months with osimertinib for EGFR-sensitizing NSCLC (FLAURA study) [2,3].